Velocity-tuning of somatosensory EEG predicts the pleasantness of gentle caress

Numerous studies have established an inverted u-shaped effect between the velocity of a caress and its pleasantness and linked this effect to the C-tactile (CT) system considered central for physical and mental health. This study probed whether cortical somatosensory representations predict and explain the inverted u-shaped effect and addressed associated individual differences. Study participants (N = 90) rated the pleasantness of stroking at varying velocities while their electroencephalogram was being recorded. An analysis across all participants replicated a preference for intermediate velocities, while a cluster analysis discriminated individuals who preferred slow (N = 43) from those who preferred fast stroking (N = 47). In both groups, intermediate velocities maximized amplitudes of a somatosensory event-related potential referred to as sN400, in line with the average rating effect. By contrast, group differences emerged in how velocity modulated a late positive potential (LPP) and Rolandic power. Notably, both the sN400 and the velocity-tuning of LPP and Rolandic power predicted the participants’ pleasantness ratings. Participants were more likely to prefer slow over fast stroking the better their LPP and Rolandic power differentiated between different velocities. Together, these results shed light on the complexity of tactile affect. They corroborate an average preference for intermediate velocities that relates to largely shared effects of CT-targeted touch on the activity of somatosensory cortex. Additionally, they identify individual differences as a function of how accurately somatosensory cortex represents the velocity of peripheral input and suggest these differences are relevant for the extent to which individuals pursue beneficial, CT-targeted touch

Stroking trajectory shapes velocity effects on pleasantness and other touch percepts.

Research has identified an inverted u-shaped relationship between stroking velocity and perceived pleasantness. However, the generalizability of this relationship is questionable as much of the work relied on the rotary tactile stimulator (RTS), which strokes skin with force varying along an arc, but confounds stimulus velocity with duration. We explored how these parameters shape the subjective evaluation of touch. In Study 1, one group of participants was stroked by the RTS, while two other groups were stroked by a new robot capable of different types of skin stroking. Participants were stroked at five velocities and rated pleasantness, humanness, intensity, and roughness. In Study 2, participants were stroked by the new robot imitating the movement of the RTS exactly, imitating it while controlling stimulus duration, or moving linearly or ovally with both constant force and duration. Participants rated pleasantness and humanness. Although stroke velocity was related to both pleasantness and humanness in an inverted u-shaped manner, stimulus motion modulated this relationship and the association between velocity and the other ratings. Together, our results clearly link stroking velocity to the perception of touch, but highlight that this relationship is shaped by other parameters such as the duration and spatial trajectory of touch. Public Significance Statement Psychophysical research has identified an inverted u-shaped relationship between a touch's velocity and subjective pleasantness, which has guided current thinking about the processing and benefits of a gentle caress. Here, we show that this relationship depends on aspects of the tactile stimulus that, so far, have been overlooked, including the duration of skin contact and the trajectory of the touch. We find that stroking duration and trajectory shape how stroke velocity modulates subjective pleasantness, humanness, intensity, and roughness. Thus, we identify a need for research to go beyond velocity and to consider other motion features of touch, especially those that approximate human social touch outside the laboratory

Understanding sex differences in affective touch: sensory pleasantness, social comfort, and precursive experiences

Although previous research revealed sex differences in affective touch, the implicated processes and the manner in which men and women differ have been left uncertain. Here we addressed this issue in two studies examining sensory pleasure, interpersonal comfort, and touch motivators. Study 1 comprised a series of lab-based experiments in which a robot stroked 214 participants (half female) at five different velocities modulating the activity of C-tactile afferents thought to support tactile pleasantness. Average pleasantness ratings followed velocity with the typical inverted u-shape similarly in both sexes. In Study 2, 260 participants (half female) completed an online survey. Here, women were more likely than men to express touch comfort with less familiar or unknown individuals, had a greater preference for touch with other women, and felt more comfortable giving and receiving touch to the forearm. Additionally, when describing how their own experiences might motivate others to touch them affectively, women produced more negative descriptions than men. Together, these results show that, while the sexes compare in a touch's sensory pleasantness, they differ in their preceding affective experiences and how they value touch at a higher-order social level. This agrees with extant research on negative affect and stress and suggests that affective touch may be a more relevant coping mechanism for women than for men.This research was supported by the Humanities and Social Sciences Prestigious Fellowship Scheme (34000219) awarded to AS by the Research Grants Council of Hong Kong

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo